Select a medication above to begin.
Penpulimab (penpulimab-kcqx)
penpulimab
Adult Dosing .
Dosage forms: INJ
New FDA Approval: April 2025
- [content coming soon]
non-keratinizing nasopharyngeal CA, recurrent and/or metastatic
- [content coming soon]
- Info: binds to PD-1 receptor on T-cells, blocking PD-1 pathway-mediated inhibition of anti-tumor immune response, resulting in decreased tumor growth (monoclonal antibody)
Peds Dosing .
- Dosage forms: --
New FDA Approval: April 2025
- [Peds dosing is not applicable for this drug]